Yousif Capital Management LLC Buys 189 Shares of Stryker Co. (NYSE:SYK)

Yousif Capital Management LLC increased its stake in shares of Stryker Co. (NYSE:SYK) by 0.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 52,522 shares of the medical technology company’s stock after purchasing an additional 189 shares during the quarter. Yousif Capital Management LLC’s holdings in Stryker were worth $18,911,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Alhambra Investment Management LLC lifted its holdings in Stryker by 1.5% in the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after buying an additional 29 shares during the period. Capital & Planning LLC lifted its stake in shares of Stryker by 3.6% in the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after purchasing an additional 29 shares during the period. Concord Wealth Partners lifted its stake in shares of Stryker by 2.2% in the 4th quarter. Concord Wealth Partners now owns 1,396 shares of the medical technology company’s stock valued at $503,000 after purchasing an additional 30 shares during the period. Avestar Capital LLC lifted its stake in shares of Stryker by 1.1% in the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock valued at $1,065,000 after purchasing an additional 31 shares during the period. Finally, Union Savings Bank lifted its stake in shares of Stryker by 1.0% in the 4th quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock valued at $1,138,000 after purchasing an additional 31 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research analyst reports. Stifel Nicolaus raised their target price on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Citigroup lifted their price objective on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Finally, UBS Group lifted their price objective on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $419.37.

Stryker Stock Performance

Shares of SYK opened at $392.55 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The firm has a market capitalization of $149.65 billion, a P/E ratio of 50.59, a PEG ratio of 2.78 and a beta of 0.96. The business has a fifty day moving average of $376.81 and a 200 day moving average of $363.64.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company earned $3.46 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 13.5 EPS for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st were issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date of this dividend was Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is currently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.